CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-10 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,000 | $22.66 | $23K | 23,000 |
| 2025-07-10 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −1,000 | 114,806 | ||
| 2025-07-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,362 | $19.75 | $126K | 296,947 |
| 2025-07-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −305 | $20.69 | $6K | 296,642 |
| 2025-06-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 26,250 |
| 2025-06-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,052 | $20.86 | $64K | 23,198 |
| 2025-06-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −198 | $21.66 | $4K | 23,000 |
| 2025-06-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 115,806 | ||
| 2025-06-20 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −12,500 | $21.40 | $267K | 965,188 |
| 2025-06-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −10,502 | $22.08 | $232K | 954,890 |
| 2025-06-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −1,998 | $22.75 | $45K | 952,892 |
| 2025-06-13 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,000 | $2.48 | $7K | 26,000 |
| 2025-06-13 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,000 | $22.55 | $68K | 23,000 |
| 2025-06-13 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,000 | 119,056 | ||
| 2025-06-09 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,607 | $20.33 | $134K | 303,369 |
| 2025-06-09 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −60 | $21.16 | $1K | 303,309 |
| 2025-06-03 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −7,500 | $20.03 | $150K | 977,688 |
| 2025-06-03 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −7,500 | $20.05 | $150K | 965,392 |
| 2025-05-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 26,250 |
| 2025-05-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $16.18 | $53K | 23,000 |
Page 10 of 37 · 724 trades